Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.49 |
| ▸ | CTSD | P07339 | 5/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | CTSE | P14091 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843127 | 0.77 | BACE1 (0.64) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL5100468 | 0.73 | BACE1 (0.71) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL4016273 | 0.72 | BACE1 (0.64) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL4843153 | 0.72 | BACE1 (0.61) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL5103493 | 0.71 | BACE1 (0.71) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL5096533 | 0.71 | BACE1 (0.73) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL5103787 | 0.70 | BACE1 (0.67) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL4911547 | 0.69 | BACE1 (0.68) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL4883545 | 0.67 | BACE1 (0.67) | BACE1CTSDBACE2CTSE | |
| SCHEMBL4066453 | 0.66 | BACE1 (1.00) | BACE1CTSDBACE2KCNH2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007145571-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |